The preoperative management of dabigatran and its specific antidote idarucizumab in patients with nonvalvular atrial fibrillation: Case reports
Dabigatran is a novel oral anticoagulant preferred due to its ease of use, favorable pharmacokinetics, decreased potential for drug-drug interactions, and the lack of monitoring requirements. With the growing use of dabigatran, it is important to highlight that dabigatran increases the risk of hemor...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | srp |
| Published: |
Pharmaceutical Association of Serbia, Belgrade, Serbia
2020-01-01
|
| Series: | Arhiv za farmaciju |
| Subjects: | |
| Online Access: | https://scindeks-clanci.ceon.rs/data/pdf/0004-1963/2020/0004-19632005310T.pdf |